Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dys beta lipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.

Target	ApoE
Reactivity	Human
Host	Mouse
Clonality	Monoclonal
Tested Applications	ELISA, WB, IHC, FCM
Recommended dilutions	ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000, FCM: 1/200 - 1/400. Optimal dilutions/concentrations should be determined by the end user.
Immunogen	Purified recombinant fragment of human ApoE expressed in E. Coli.
Purification	Unpurified Ascites.
Isotype	IgG1
Conjugation	Unconjugated
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Molecular Weight	36 kDa
Swiss Prot	P02649
GeneID	348
Gene Symbol	APOE
OMIM	107741
HGNC	613
Ensembl	ENSG00000130203
Buffer	Ascitic fluid containing 0.03% sodium azide.
UNSPSC Code	12352203
Availability	Shipped within 5-10 working days.
Note	This product is for research use only.